Amgen Inc (AMGN) 157.19 $AMGN
Market News: Amgen, Inc., The Madison Square Garden Co, Twitter Inc
at The Street - 16 mins ago
Economists expected policy makers to maintain low interests rates for a considerable timeThe stock markets in the United States rallied today as investors evaluate data and corporate earnings prior to...
MSG: 72.99 (+7.21), AMGN: 157.19 (+8.99), TWTR: 43.78 (-4.78)
Stocks rise as profits, confidence index climb
By BERNARD CONDON - AP - 15 mins ago
NEW YORK (AP) — Strong corporate earnings pushed up stocks across industries on Tuesday, with the energy sector and small companies leading the gains.
MSG: 72.99 (+7.21), AMGN: 157.19 (+8.99), WFC: 51.78 (+0.47)
Twitter and Amgen are big market movers
AP - 21 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.33 (-1.16), KSS: 54.66 (-3.89), MU: 32.61 (+0.31), PFE: 29.09 (+0.06), HAL: 53.26 (+0.87), AMGN: 157.19 (+8.99), NQ: 8.00 (-1.46), RGC: 21.28 (+0.77), MS: 34.36 (+0.40), MSG: 72.99 (+7.21), NVAX: 5.48 (-0.32), CQB: 14.39 (+0.03), SRPT: 15.12 (-0.79), RCPT: 95.76 (+28.02), TWTR: 43.78 (-4.78), PTIE: 2.07 (+0.12)
Amgen Set to Possibly Pullback After Yesterday's Rally of 6.07%
Comtex SmarTrend(R) - 23 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 157.19 (+8.99)
After Yesterday's Rally of 6.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 23 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 157.19 (+8.99)
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
PR Newswire - 1 hr 4 mins ago
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb®5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.
AMGN: 157.19 (+8.99), XNCR: 10.60 (+0.04)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - 2 hrs 46 mins ago
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 157.19 (+8.99), ABBV: 60.93 (+0.44)
Midday Glance: Biotechnology companies
AP - Tue Oct 28, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Pfizer Beats Earnings, But Lacks Year-over-Year EPS Growth - Stocks in the News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:17PM CDT
Pfizer (PFE) stock is in focus following its latest EPS report.
AZN: 71.43 (+0.67), PFE: 29.09 (+0.06), AMGN: 157.19 (+8.99)
Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 157.19 (+8.99), RCPT: 95.76 (+28.02), NVS: 92.35 (+2.14)
Amgen (AMGN) Stock Is Climbing Today Following Earnings Release
at The Street - Tue Oct 28, 11:24AM CDT
Amgen (AMGN) shares are climbing after the biotech company beat earnings estimates, raised its quarterly dividend, and provided strong full year guidance.
AMGN: 157.19 (+8.99)
Stocks Extend Gains As Alibaba, Tesla Rally
at Investor's Business Daily - Tue Oct 28, 11:04AM CDT
Major averages extended their gains in late-morning trading amid earnings reports and a surprisingly strong consumer confidence reading. The Nasdaq rallied 1.2%, the S&P 500 gained 0.6% and the Dow was up 0.4%. Volume was tracking higher on the...
TSLA: 242.77 (+21.10), AMGN: 157.19 (+8.99), AAPL: 106.74 (+1.63), BABA: 99.68 (+1.89), CELG: 105.70 (+2.60)
Amgen (AMGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 10:37AM CDT
The following Amgen (AMGN) conference call took place on October 27, 2014, 05:00 PM ET. This is a transcript of that earnings call:
AMGN: 157.19 (+8.99)
Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing
at Investor's Business Daily - Tue Oct 28, 9:36AM CDT
Stocks climbed in mixed early trade Tuesday, aided by data showing an unexpected jump in October consumer confidence. The Nasdaq led with a 0.9% gain, with volume up 12% vs. levels early Monday. The S&P 500 tacked on a 0.5% gain. The Dow Jones...
LCI: 53.16 (+1.70), SAVE: 71.06 (+4.69), PH: 122.95 (+5.71), AMGN: 157.19 (+8.99)
Early Glance: Biotechnology companies
AP - Tue Oct 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Amgen Beats on Q3 Earnings & Revenues, Ups View Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Oct 28, 8:10AM CDT
Amgen (AMGN), which has performed above expectations over the past few quarters, raised its 2014 guidance yet again.
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), AMGN: 157.19 (+8.99), NVS: 92.35 (+2.14)
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans
PR Newswire - Tue Oct 28, 7:48AM CDT
Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015.
AMGN: 157.19 (+8.99)
'Fast Money' Recap: Is It Still Worth Investing in Twitter?
at The Street - Tue Oct 28, 4:00AM CDT
The trading panel discussed Twitter's earnings and what to watch for Tuesday with Facebook and Buffalo Wild Wings.
TSLA: 242.77 (+21.10), GPRO: 69.30 (+4.39), MU: 32.61 (+0.31), NKE: 92.45 (+0.81), FB: 80.77 (+0.49), HAL: 53.26 (+0.87), XOM: 95.10 (+1.39), AMGN: 157.19 (+8.99), M: 57.27 (-1.22), CLF: 11.29 (+2.05), BWLD: 151.68 (+17.86), MTW: 20.21 (+1.30), SLB: 96.51 (+2.99), TWTR: 43.78 (-4.78), WEN: 8.07 (+0.06), BHI: 52.10 (+0.97)
Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Oct 27, 11:59PM CDT
Amgen had a solid beat on earnings, and AMGN stock was rising after hours.
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Global and China Monoclonal Antibody Industry Report, 2014-2019
PR Newswire - Mon Oct 27, 8:26PM CDT
Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years.
JNJ: 104.79 (+0.72), AMGN: 157.19 (+8.99), NVS: 92.35 (+2.14)
Market News: Amgen, Inc., The Madison Square Garden Co, Twitter Inc
at The Street - 16 mins ago
Economists expected policy makers to maintain low interests rates for a considerable timeThe stock markets in the United States rallied today as investors evaluate data and corporate earnings prior to...
MSG: 72.99 (+7.21), AMGN: 157.19 (+8.99), TWTR: 43.78 (-4.78)
Stocks rise as profits, confidence index climb
By BERNARD CONDON - AP - 15 mins ago
NEW YORK (AP) — Strong corporate earnings pushed up stocks across industries on Tuesday, with the energy sector and small companies leading the gains.
MSG: 72.99 (+7.21), AMGN: 157.19 (+8.99), WFC: 51.78 (+0.47)
Twitter and Amgen are big market movers
AP - 21 mins ago
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
AMKR: 6.33 (-1.16), KSS: 54.66 (-3.89), MU: 32.61 (+0.31), PFE: 29.09 (+0.06), HAL: 53.26 (+0.87), AMGN: 157.19 (+8.99), NQ: 8.00 (-1.46), RGC: 21.28 (+0.77), MS: 34.36 (+0.40), MSG: 72.99 (+7.21), NVAX: 5.48 (-0.32), CQB: 14.39 (+0.03), SRPT: 15.12 (-0.79), RCPT: 95.76 (+28.02), TWTR: 43.78 (-4.78), PTIE: 2.07 (+0.12)
Amgen Set to Possibly Pullback After Yesterday's Rally of 6.07%
Comtex SmarTrend(R) - 23 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 157.19 (+8.99)
After Yesterday's Rally of 6.07% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 23 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.47 to a high of $157.25. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $148.47 on volume of 11.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 157.19 (+8.99)
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease
PR Newswire - 1 hr 4 mins ago
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has regained all development and commercial rights to XmAb®5871 by seeking and obtaining a termination of the prior option and collaboration agreement and executing a new right-of-first-negotiation agreement with Amgen. XmAb5871 is a first-in-class monoclonal antibody containing Xencor's proprietary immune inhibitor XmAb Fc domain that targets FcRIIb to inhibit B-cell function. XmAb5871 is currently in a Phase 1b/2a clinical trial in patients with moderate-to-severe rheumatoid arthritis (RA) and topline results are expected by the end of 2014. The company is planning clinical development in multiple autoimmune diseases where B-cell inhibition shows promise, including IgG4-related disease.
AMGN: 157.19 (+8.99), XNCR: 10.60 (+0.04)
Amgen Refuses To Split, But Plans Hearten Investors
at Investor's Business Daily - 2 hrs 46 mins ago
Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday's Q3 earnings beat, Amgen's action helped drive the stock up more than 5% in afternoon...
AMGN: 157.19 (+8.99), ABBV: 60.93 (+0.44)
Midday Glance: Biotechnology companies
AP - Tue Oct 28, 12:25PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Pfizer Beats Earnings, But Lacks Year-over-Year EPS Growth - Stocks in the News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:17PM CDT
Pfizer (PFE) stock is in focus following its latest EPS report.
AZN: 71.43 (+0.67), PFE: 29.09 (+0.06), AMGN: 157.19 (+8.99)
Health Care Stocks On The Rise With Help From 3 Stocks
at The Street - Tue Oct 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
AMGN: 157.19 (+8.99), RCPT: 95.76 (+28.02), NVS: 92.35 (+2.14)
Amgen (AMGN) Stock Is Climbing Today Following Earnings Release
at The Street - Tue Oct 28, 11:24AM CDT
Amgen (AMGN) shares are climbing after the biotech company beat earnings estimates, raised its quarterly dividend, and provided strong full year guidance.
AMGN: 157.19 (+8.99)
Stocks Extend Gains As Alibaba, Tesla Rally
at Investor's Business Daily - Tue Oct 28, 11:04AM CDT
Major averages extended their gains in late-morning trading amid earnings reports and a surprisingly strong consumer confidence reading. The Nasdaq rallied 1.2%, the S&P 500 gained 0.6% and the Dow was up 0.4%. Volume was tracking higher on the...
TSLA: 242.77 (+21.10), AMGN: 157.19 (+8.99), AAPL: 106.74 (+1.63), BABA: 99.68 (+1.89), CELG: 105.70 (+2.60)
Amgen (AMGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 10:37AM CDT
The following Amgen (AMGN) conference call took place on October 27, 2014, 05:00 PM ET. This is a transcript of that earnings call:
AMGN: 157.19 (+8.99)
Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing
at Investor's Business Daily - Tue Oct 28, 9:36AM CDT
Stocks climbed in mixed early trade Tuesday, aided by data showing an unexpected jump in October consumer confidence. The Nasdaq led with a 0.9% gain, with volume up 12% vs. levels early Monday. The S&P 500 tacked on a 0.5% gain. The Dow Jones...
LCI: 53.16 (+1.70), SAVE: 71.06 (+4.69), PH: 122.95 (+5.71), AMGN: 157.19 (+8.99)
Early Glance: Biotechnology companies
AP - Tue Oct 28, 9:33AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Amgen Beats on Q3 Earnings & Revenues, Ups View Again - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Oct 28, 8:10AM CDT
Amgen (AMGN), which has performed above expectations over the past few quarters, raised its 2014 guidance yet again.
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), AMGN: 157.19 (+8.99), NVS: 92.35 (+2.14)
Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans
PR Newswire - Tue Oct 28, 7:48AM CDT
Amgen (NASDAQ:AMGN) today outlined the Company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015.
AMGN: 157.19 (+8.99)
'Fast Money' Recap: Is It Still Worth Investing in Twitter?
at The Street - Tue Oct 28, 4:00AM CDT
The trading panel discussed Twitter's earnings and what to watch for Tuesday with Facebook and Buffalo Wild Wings.
TSLA: 242.77 (+21.10), GPRO: 69.30 (+4.39), MU: 32.61 (+0.31), NKE: 92.45 (+0.81), FB: 80.77 (+0.49), HAL: 53.26 (+0.87), XOM: 95.10 (+1.39), AMGN: 157.19 (+8.99), M: 57.27 (-1.22), CLF: 11.29 (+2.05), BWLD: 151.68 (+17.86), MTW: 20.21 (+1.30), SLB: 96.51 (+2.99), TWTR: 43.78 (-4.78), WEN: 8.07 (+0.06), BHI: 52.10 (+0.97)
Amgen Beats Earnings Estimates, What's Next for AMGN? - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Mon Oct 27, 11:59PM CDT
Amgen had a solid beat on earnings, and AMGN stock was rising after hours.
GILD: 113.45 (+0.86), AMGN: 157.19 (+8.99), CELG: 105.70 (+2.60)
Global and China Monoclonal Antibody Industry Report, 2014-2019
PR Newswire - Mon Oct 27, 8:26PM CDT
Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years.
JNJ: 104.79 (+0.72), AMGN: 157.19 (+8.99), NVS: 92.35 (+2.14)
